Older Breast Cancer Patients: Risk For Cognitive Decline
Description: PUBLIC HEALTH RELEVANCE: Cognitive decline is an important public health issue facing our aging nation since it is a strong predictor of functional decline, hospital admission, mortalit, and healthcare costs. While there are compelling data indicating that cancer and its therapies are associated with cognitive decline ("chemo-brain'), there are no large-scale prospective studies of decline in older survivors. Our multi-disciplinary, national team proposes to conduct long-term follow-up of older (age 60+) breast cancer survivors from the Thinking and Living with Cancer (TLC) cohort and their matched non-cancer controls to identify how lifestyle, health, and psychosocial factors and biomarkers (including genotype and circulating inflammation levels) affect risk for and trajectories of cognitive decline over 48 months; the findings will suggest future mechanistic research and intervention trials, support patient-physician discussions about treatment benefits and harms, and improve survivorship care planning for older breast cancer survivors.
Funder: National Cancer Institute
Funding type: research
Funder scheme: R01
Start date: 2007-07-01
End date: 2021-11-30
Investigator: TIM ALAN AHLES
Institution: GEORGETOWN UNIVERSITY
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 177
Funder award ID: R01CA129769
OpenAlex ID: G8926351850